JAMA : the journal of the American Medical Association

• Latest
• Best
• Search…

• JAMA · Dec 2023

  Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.

  The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain. ⋯ Among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of COVID-19 symptoms.

  explore further… or not…

• JAMA · Dec 2023

  Comment Letter Comparative Study

  Manchester Procedure vs Sacrospinous Hysteropexy for Pelvic Organ Prolapse.

  no abstract available

  keep going… or not…

• JAMA · Dec 2023

  Sudden Cardiac Deaths Have Decreased Among Young Athletes.

  no abstract available

  expand abstract… or not…

• JAMA · Dec 2023

  First At-Home Test for Chlamydia and Gonorrhea Receives FDA Approval.

  no abstract available

  expand abstract… or not…

• JAMA · Dec 2023

  Reimbursement to Pharmacies for Generic Drugs by Medicare Part D Sponsors.

  no abstract available

  read more… mark as read…